Cargando…
Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374065/ https://www.ncbi.nlm.nih.gov/pubmed/35946524 http://dx.doi.org/10.1097/CAD.0000000000001368 |
_version_ | 1784767715440852992 |
---|---|
author | Cheng, Daoan Tang, Shuxian Li, Dong Zhao, Weiqing Wei, Wei Fang, Cheng Ji, Mei |
author_facet | Cheng, Daoan Tang, Shuxian Li, Dong Zhao, Weiqing Wei, Wei Fang, Cheng Ji, Mei |
author_sort | Cheng, Daoan |
collection | PubMed |
description | Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient after osimertinib resistance who was successfully treated by high-dose furmonertinib (AST2818) at 160 mg. The patient initially received the GCP regimen for 11 months and displayed partial response. The patient received osimertinib 80 mg at the time of progression with a stable clinical and radiological response lasting only 7 months. Subsequently, she was commenced on furmonertinib 160 mg once daily. After 2 weeks of furmonertinib, the patient’s tumor was markedly smaller on a follow-up chest CT scan, and her respiratory symptoms also improved. What shocked us was that after a month’s re-examination of the cranial MRI, the intracranial lesions wholly disappeared. This report provides a case of the successful rescue of osimertinib-resistant NSCLC patients by oral administration of high-dose furmonertinib 160 mg daily, providing a new treatment option for osimertinib-resistant patients. |
format | Online Article Text |
id | pubmed-9374065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-93740652022-08-19 Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report Cheng, Daoan Tang, Shuxian Li, Dong Zhao, Weiqing Wei, Wei Fang, Cheng Ji, Mei Anticancer Drugs Case Reports Osimertinib, the third generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, responds well to advanced non–small-cell lung cancer (NSCLC) with the EGFR T790M mutation. However, resistance to osimertinib would inevitably occur. We report a case of an advanced NSCLC patient after osimertinib resistance who was successfully treated by high-dose furmonertinib (AST2818) at 160 mg. The patient initially received the GCP regimen for 11 months and displayed partial response. The patient received osimertinib 80 mg at the time of progression with a stable clinical and radiological response lasting only 7 months. Subsequently, she was commenced on furmonertinib 160 mg once daily. After 2 weeks of furmonertinib, the patient’s tumor was markedly smaller on a follow-up chest CT scan, and her respiratory symptoms also improved. What shocked us was that after a month’s re-examination of the cranial MRI, the intracranial lesions wholly disappeared. This report provides a case of the successful rescue of osimertinib-resistant NSCLC patients by oral administration of high-dose furmonertinib 160 mg daily, providing a new treatment option for osimertinib-resistant patients. Lippincott Williams & Wilkins 2022-08-10 2022-09 /pmc/articles/PMC9374065/ /pubmed/35946524 http://dx.doi.org/10.1097/CAD.0000000000001368 Text en Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Reports Cheng, Daoan Tang, Shuxian Li, Dong Zhao, Weiqing Wei, Wei Fang, Cheng Ji, Mei Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report |
title | Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report |
title_full | Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report |
title_fullStr | Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report |
title_full_unstemmed | Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report |
title_short | Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report |
title_sort | successful salvage therapy using high-dose furmonertinib (ast2818) for non–small-cell lung cancer after osimertinib resistance: a case report |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374065/ https://www.ncbi.nlm.nih.gov/pubmed/35946524 http://dx.doi.org/10.1097/CAD.0000000000001368 |
work_keys_str_mv | AT chengdaoan successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport AT tangshuxian successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport AT lidong successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport AT zhaoweiqing successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport AT weiwei successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport AT fangcheng successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport AT jimei successfulsalvagetherapyusinghighdosefurmonertinibast2818fornonsmallcelllungcancerafterosimertinibresistanceacasereport |